Activated protein C in sepsis and beyond: Update 2006

Frontiers in Bioscience

Volumn 12, Issue 5, 2007, Pages 1963-1972

  Toltl, Lisa J ^a   Shin, Lucy Y Y ^a   Liaw, Patricia C Y ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Activated protein C; Apoptosis; Coagulation; EPCR; Inflammation; PAR receptors; Review; Sepsis; Vascular dysfunction

Indexed keywords

EID: 34249786231     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2202     Document Type: Article

References (90)

1. Wheeler, A. P. & G. R. Bernard: Treating patients with severe sepsis. N Engl J Med 340, 207-214 (1999)
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo & M. R. Pinsky: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29, 1303-1310 (2001)
3. Riedemann, N. C., R. F. Guo & P. A. Ward: Novel strategies for the treatment of sepsis. Nat Med 9, 517-524 (2003)
4. Warren, B. L., A. Eid, P. Singer, S. S. Pillay, P. Carl, I. Novak, P. Chalupa, A. Atherstone, I. Penzes, A. Kubler, S. Knaub, H. O. Keinecke, H. Heinrichs, F. Schindel, M. Juers, R. C. Bone & S. M. Opal: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286, 1869-1878 (2001)
5. Abraham, E., K. Reinhart, S. Opal, I. Demeyer, C. Doig, A. L. Rodriguez, R. Beale, P. Svoboda, P. F. Laterre, S. Simon, B. Light, H. Spapen, J. Stone, A. Seibert, C. Peckelsen, C. De Deyne, R. Postier, V. Pettila, A. Artigas, S. R. Percell, V. Shu, C. Zwingelstein, J. Tobias, L. Poole, J. C. Stolzenbach & A. A. Creasey: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238-247 (2003)
6. Esmon, C.: The protein C pathway. Crit Care Med 28, S44-S48 (2000)
7. Grinnell, B. W. & D. Joyce: Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit Care Med 29, S53-S60 (2001)
8. Stefanec, T.: Endothelial apoptosis: could it have a role in the pathogenesis and treatment of disease? Chest 117, 841-854 (2000)
9. Bernard, G. R., J. L. Vincent, P. F. Laterre, S. P. LaRosa, J. F. Dhainaut, A. Lopez-Rodriguez, J. S. Steingrub, G. E. Garber, J. D. Helterbrand, E. W. Ely & C. J. Fisher, Jr.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344, 699-709 (2001)
10. Lane, D. A., P. M. Mannucci, K. A. Bauer, R. M. Bertina, N. P. Bochkov, V. Boulyjenkov, M. Chandy, B. Dahlback, E. K. Ginter, J. P. Miletich, F. R. Rosendaal & U. Seligsohn: Inherited thrombophilia: Part 1. Thromb Haemost 76, 651-662 (1996)
11. Lane, D. A., P. M. Mannucci, K. A. Bauer, R. M. Bertina, N. P. Bochkov, V. Boulyjenkov, M. Chandy, B. Dahlback, E. K. Ginter, J. P. Miletich, F. R. Rosendaal & U. Seligsohn: Inherited thrombophilia: Part 2. Thromb Haemost 76, 824-834 (1996)
12. Norlund, L., J. Holm, B. Zoller & A. K. Ohlin: A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 77, 248-251 (1997)
13. Doggen, C. J., V. M. Cats, R. M. Bertina & F. R. Rosendaal: Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97, 1037-1041 (1998)
14. Rosendaal, F. R., D. S. Siscovick, S. M. Schwartz, R. K. Beverly, B. M. Psaty, W. T. Longstreth, Jr., T. E. Raghunathan, T. D. Koepsell & P. H. Reitsma: Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood '89, 2817-2821(1997)
15. Lane, D. A. & P. J. Grant: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95, 1517-1532 (2000)
16. Grey, S. T., A. Tsuchida, H. Hau, C. L. Orthner, H. H. Salem & W.W. Hancock: Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorol ester. J Immunol 153, 3664-3672 (1994)
17. White, B., M. Schmidt, C. Murphy, W. Livingstone, D. O'Toole, M. Lawler, L. O'Neill, D. Kelleher, H. P. Schwarz & O. P. Smith: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 110, 130-134 (2000)
18. Yuksel, M, K. Okajima, M. Uchiba, S. Horiuchi & H. Okabe: Activated protein C inhibits lipopolysaccharideinduced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 88, 267-273 (2002)
19. Joyce, D. E., L. Gelbert, A. Ciaccia, B. DeHoff & B. W. Grinnell: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276, 11199-11203 (2001)
20. Taylor, F. B., Jr., A. Chang, C. T. Esmon, A. D'Angelo, S. Vigano-D'Angelo & K. E. Blick: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79, 918-925 (1987)
21. Murakami, K., K. Okajima, M. Uchiba, M. Johno, T. Nakagaki, H. Okabe, & K. Takatsuki: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272, L197-L202 (1997)
22. Murakami, K., K. Okajima, M. Uchiba, M. Johno, T. Nakagaki, H. Okabe & K. Takatsuki: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87, 642-647 (1996)
23. Esmon, C. T.: The endothelial cell protein C receptor. Thromb Haemost 83, 639-643 (2000)
24. Riewald, M., R. J. Petrovan, A. Donner, B. M. Mueller & W. Ruf: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880-1882 (2002)
25. Mosnier, L. O. & J. H. Griffin: Inhibition of staurosporineinduced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 373, 65-70 (2003)
26. Cheng, T., D. Liu, J. H. Griffin, J. A. Fernandez, F. Castellino, E. D. Rosen, K. Fukudome & B. V. Zlokovic: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 9, 338-342 (2003)
27. Coughlin, S. R.: Protease-activated receptors in vascular biology. Thromb Haemost 86, 298-307 (2001)
28. Feistritzer, C. & M. Riewald: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105, 3178-3184 (2005)
29. Finigan, J. H., S. M. Dudek, P. A. Singleton, E. T. Chiang, J. R. Jacobson, S. M. Camp, S. Q. Ye & J. G. Garcia: Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280, 17286-17293 (2005)
30. Guo, H., D. Liu, H. Gelbard, T. Cheng, R. Insalaco, J. A. Fernandez, J. H. Griffin & B. V. Zlokovic: Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41, 563-572 (2004)
31. Sarti, C., D. Rastenyte, Z. Cepaitis & J. Tuomilehto: International trends in mortality from stroke, 1968 to 1994. Stroke 31, 1588-1601 (2000)
32. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Eng J Med 333, 1581-1587 (1995)
33. Frey, J. L.: Recombinant tissue plasminogen activator (rtPA) for stroke. The perspective at 8 years. Neurologist 11, 123-133 (2005)
34. Lo, E. H., J. P. Broderick & M. A. Moskowitz: tPA and proteolysis in the neurovascular unit. Stroke 35, 354-356 (2004)
35. Wang, Y. F., S. E. Tsirka, S. Strickland, P. E. Stieg, S. G. Soriano & S. A. Lipton: Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 4, 228-231 (1998)
36. Flavin, M. P., G. Zhao & L. T. Ho: Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Glia 29, 347-354 (2000)
37. Shibata, M., S. R. Kumar, A. Amar, J. A. Fernandez, F. Hofman, J. H. Griffin & B. V. Zlokovic: Antiinflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103, 1799-1805 (2001)
38. Domotor, E., O. Benzakour, J. H. Griffin, D. Yule, K. Fukudome & B. V. Zlokovic: Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 101, 4797-4801 (2003)
39. Liu, D., T. Cheng, H. Guo, J. A. Fernandez, J. H. Griffin, X. Song & B. V. Zlokovic: Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 10, 1379-1383 (2004)
40. Zlokovic, B. V., C. Zhang, D. Liu, J. Fernandez, J. H. Griffin & M. Chopp: Functional recovery after embolic stroke in rodents by activated protein C. Ann Neural 58, 474-477 (2005)
41. Arumugam, T. V., I. A. Shiels, T. M. Woodruff, D. N. Granger & S. M. Taylor: The role of the complement system in ischemia-reperrusion injury. Shock 21, 401-409 (2004)
42. Garden, D. L. & D. N. Granger: Pathophysiology of ischaemia-reperrusion injury. JPathol 190, 255-266 (2000)
43. Seal, J. B. & B. L. Gewertz: Vascular dysfunction in ischemia-reperrusion injury. Ann Vase Surg 19, 572-584 (2005)
44. Dillon, J. P., A. J. Laing, R. A. Cahill, G. C. O'Brien, J. T. Street, J. H. Wang, G. A. Me & H. P. Redmond: Activated protein C attenuates acute ischaemia reperfusion injury in skeletal muscle. J Orthop Res 23, 1454-1459 (2005)
45. Mizutani, A., K. Okajima, M. Uchiba & T. Noguchi: Activated protein C reduces ischemia/reperrusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 95, 3781-3787 (2000)
46. Hirose, K., K. Okajima, Y. Taoka, M. Uchiba, H. Tagami, K, Nakano, J. Utoh, H. Okabe & N. Kitamura: Activated protein C reduces the ischemia/reperfusioninduced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 232, 272-280 (2000)
47. Schoots, I. G., M. Levi, A. K. van Vliet, A. M. Maas, E. H. Roossink & T. M. van Gulik: Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 32, 1375-1383 (2004)
48. Yamaguchi, Y., N. Hisama, K. Okajima, M. Uchiba, K. Murakami, Y. Takahashi, S. Yamada, K. Mori & M. Ogawa: Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver. Hepatology 25, 1136-1140 (1997)
49. Thannickal, V. J., G. B. Toews, E. S. White, J. P. Lynch, III & F. J. Mart Inez: Mechanisms of pulmonary fibrosis. Annu Rev Med 55, 395-417 (2004)
50. Reynolds, H. Y.: Lung inflammation and fibrosis: an alveolar macrophage-centered perspective from the 1970s to 1980s. Am J Respir Crit Care Med 171, 98-102 (2005)
51. Chambers, R. C.: Role of coagulation cascade proteases in lung repair and fibrosis. Ear Respir J Suppl 44, 33s-35s (2003)
52. Imokawa, S., A. Sato, H. Hayakawa, M. Kotani, T. Urano & A. Takada: Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 156, 631-636 (1997)
53. Eitzman, D. T., R. D. McCoy, X. Zheng, W. P. Fay, T. Shen, D. Ginsburg & R. H. Simon: Bleomycininduced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97, 232-237 (1996)
54. Yasui, H., E. C. Gabazza, S. Tamaki, T. Kobayashi, O. Hataji, H. Yuda, S. Shimizu, K. Suzuki, Y. Adachi & O. Taguchi: Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 163, 1660-1668 (2001)
55. Schwarz, M. A.: Acute lung injury: cellular mechanisms and derangements, Paediatr Respir Rev 2, 3-9 (2001)
56. Hammer, J.: Acute lung injury: pathophysiology, assessment and current therapy. Paediatr Respir Re. 2, 10-21 (2001)
57. MacCallum, N. S. & T. W. Evans: Epidemiology of acute lung injury. Curr Opin Crit Care 11, 43-49 (2005)
58. Schultz, M. J., J. J. Haitsma, H. Zhang & A. S. Slutsky: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia-a review. Crit Care Med 34, 871-877 (2006)
59. Nick, J. A., C. D. Coldren, M. W. Geraci, K. R. Poch, B. W. Fouty, J. O'Brien, M. Gruber, S. Zarini, R. C. Murphy, K. Kuhn, D. Richter, K. R. Kast & E. Abraham: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104, 3878-3885 (2004)
60. Corry, D. B. & F. Kheradmand: The future of asthma therapy: integrating clinical and experimental studies. Immunol Res 33, 35-52 (2005)
61. Barrios, R. J., F. Kheradmand, L. Batts & D. B. Corry: Asthma: pathology and pathophysiology. Arch Pathol Lab Med 130, 447-451 (2006)
62. Busse, W. W. & R. F. Lemanske, Jr.: Asthma. N Engl J Med 344, 350-362 (2001)
63. Gabazza, E. C., O. Taguchi, S. Tamaki, H. Takeya, H. Kobayashi, H. Yasui, T. Kobayashi, O. Hataji, H. Urano, H. Zhou, K. Suzuki & Y. Adachi: Thrombin in the airways of asthmatic patients. Lung 177, 253-262 (1999)
64. Hataji, O., O. Taguchi, E. C. Gabazza, H. Yuda, H. Fujimoto, K. Suzuki & Y. Adachi: Activation of protein C pathway in the airways. Lung 180, 47-59 (2002)
65. Parameswaran, K., P. M. O'Byrne & M. R. Sears: Inhaled corticosteroids for asthma: common clinical quandaries. J Asthma 40, 107-118 (2003)
66. Kuperman, D. A., X. Huang, L. L. Koth, G. H. Chang, G. M. Dolganov, Z. Zhu, J. A. Elias, D. Sheppard, and D. J. ErDirect effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat.Med. 8:885-889 (2002)
67. Steinberg, W. & S. Tenner: Acute pancreatitis. N Engl J Med 330, 1198-1210 (1994)
68. Wilson, P. G., M. Manji & J. P. Neoptolemos: Acute pancreatitis as a model of sepsis. J Antimicrob Chemother 41, Suppl A:51-63 (1998)
69. Pandol, S. J.: Acute pancreatitis. Curr Opin Gastroenterol 21, 538-543 (2005)
70. Baron, T. H. & D. E. Morgan: Acute necrotizing pancreatitis, N EngJ Med 340, 1412-1417 (1999)
71. Altavilla, D., C. Famulari, M. Passaniti, M. Galeano, A. Maori, P. Seminara, L. Minutoli, H. Marini, M. Calo, F. S. Venuti, M. Esposito & F. Squadrito: Attenuated cerulein-induced pancreatitis in nuclear factor-kappaBdeficient mice. Lab Invest 83, 1723-1732 (2003)
72. Joyce, D. E. & B. W. Grinnell: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 30, S288-S293 (2002)
73. Yamenel, L., M. R. Mas, B. Comert, A. T. Isik, S. Aydin, N. Mas, S. Deveci, M. Ozyurt, I. Tasci & T, Unal: The effect of activated protein C on experimental acute necrotizing pancreatitis. Crit Care 9, R184-R190 (2005)
74. Radenkovic, D., D. Bajec, A. Karamarkovic, B. Stefanovic, N. Milic, S. Ignjatovic, P. Gregoric & M. Milicevic: Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas 29:152-156 (2004)
75. Lindstrom, O., L. Kylanpaa, P. Mentula, P. Puolakkainen, E. Kemppainen, R. Haapiainen, J. A. Fernandez, J. H. Griffin, H. Repo & J. Petaja: Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Crit Care 10, R16 (2006)
76. Machala, W., N. Wachowicz, A. Komorowska & W. Gaszynski: The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies. Med Sci Monit 10, CS31-CS36 (2004)
77. Xue, M., P. Thompson, I. Kelso & C. Jackson: Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. Exp Cell Res 299, 119-127(2004)
78. Xue, M., D. Campbell, P. N. Sambrook, K. Fukudome & C. J. Jackson: Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. J Invest Dermatol 125, 1279-1285 (2005)
79. Jackson, C. J., M. Xue, P. Thompson, R. A. Davey, K. Whitmont, S. Smith, N. Buisson-Legendre, T. Sztynda, L. J. Furphy, A. Cooper, P. Sambrook & L. March: Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen 13, 284-294 (2005)
80. Uchiba, M., K. Okajima, Y. Oike, Y. Ito, K. Fukudome, H. Isobe & T. Suda: Activated protein C induces endothelial cell proliferation by mitogenactivated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 95, 34-41 (2004)
81. Brueckmann, M., S. Horn, S. Lang, K. Fukudome, N. A. Schulze, U. Hoffmann, J. J. Kaden, M. Borggrefe, K. K. Haase & G. Huhle: Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor1. Thromb Haemost 93, 743-750 (2005)
82. Perez-Casal, M., C. Downey, K. Fukudome, G. Marx & C. H. Toh: Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 105, 1515-1522 (2005)
83. Feistritzer, C., R. A. Schuepbach, L. O. Mosnier, L. A. Bush, E. Di Cera, J. H. Griffin & M. Riewald: Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006)
84. Franscini, N., E. B. Bachli, N. Blau, M. S. Leikauf, A. Schaffner & G. Schoedon: Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 110, 2903-2909 (2004)
85. Shua, F., H. Kobayashia, K. Fukudomeb, N. Tsuneyoshib, M. Kimotob & T. Teraoa: Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett 477, 208-212 (2000)
86. Stephenson D.A., L.J. Toltl, S. Beaudin & P.C. Liaw: Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol in press (2006)
87. Sturn, D. H., N. C. Kaneider, C. Feistritzer, A. Djanani, K. Fukudome & C. J. Wiedermann: Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102, 1499-1505 (2003)
88. Jackson, C, J., M. Xue, P. Thompson, R. A. Davey, K. Whitmont, S. Smith, N. Buisson-Legendre, T. Sztynda, L. J. Furphy, A. Cooper, P. Sambrook & L. March: Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen 13, 284-294 (2005)
89. Nakamura, M., E. C. Gabazza, I. Imoto, Y. Yano, O. Taguchi, N. Horiki, K. Fukudome, K. Suzuki & Y. Adachi: Anti-inflammatory effect of activated protein C in gastric epithelial cells. J Thromb Haemost 3, 2721-2729 (2005)
90. Feistritzer, C., B. A. Mosheimer, D. H. Sturn, M. Riewald, J. R. Patsch & C. J. Wiedermann: Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. J. Immunol 176, 1019-1025 (2006)